EASTYLE ( D E esc A lation S tr a tegy for Optimal T icagrelor Therapy in Acute M Y ocardia L Infarction Pati E nts, prospective, multicenter, randomized) Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006950

Enrollment

2312

Registered

2022-01-21

Start date

2021-12-28

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : From the day after the procedure, all patients continue to take aspirin 100 mg daily and ticagrelor 90 mg bid. Before discharge, they are randomly assigned to the WEST strategy group, which mai

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult patients diagnosed with myocardial infarction 2. Adult patients over the age of 19 years old 3. Patients who underwent Orsiro Mission stent with more than coronary artery stenosis 4. Patients who agreed to participate in the study

Exclusion criteria

Exclusion criteria: 1. if patient disagree with the study or As judged by the investigator, it undesirable for the patient to participate in the study. 2. History of cerebral hemorrhage or intracranial hemorrhage in the past 3. Active bleeding (e.g., peptic ulcer, intracranial hemorrhage) at the time of IP medication or High risk of hemorrhage (e.g., high risk of hemorrhage for gastrointestinal lesions, high risk of hemorrhagic malignancy) 4. If you have Bleeding diathesis or coagulopathy (number of platelets before correction ) 7.0 mg/dL). In the case of uric acid nephropathy, administration is contraindicated.

Design outcomes

Primary

Measure	Time frame
NACE (net adverse clinical events): Major cardiac and cerebrovascular event for 12 months after stenting (all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke) + bleeding event (BARC type 2, 3, or 5 bleeding)	—

Secondary

Measure	Time frame
1. (MACCE, Major Adverse Cardiac and Cerebrovascular Events): all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke 2. Bleeding event ? BARC type 2, 3 or 5 bleeding ? BARC 3 or 5 bleeding ? TIMI major or minor bleeding ? GUSTO major or severe bleeding ? ISTH major bleeding 3. all-cause death 4. CV (cardiac vascular death) 5. Myocardiac infarction 6. definite or probable stent thrombosis by Academic Research Consortium (ARC) definition 7. cerebrovascular accident (stroke) 8. cardiac death or Myocardiac infarction 9. cardiac death , Myocardiac infarction or stent thrombosis 10. cardiacvascular death, Myocardiac infarction or cerebrovascular accident (stroke) 11. TLR, target lesion revascularization 12. TVR, target vessel revascularization 13. any revascularization	—

Measure

Time frame

1. (MACCE, Major Adverse Cardiac and Cerebrovascular Events): all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke 2. Bleeding event ? BARC type 2, 3 or 5 bleeding ? BARC 3 or 5 bleeding ? TIMI major or minor bleeding ? GUSTO major or severe bleeding ? ISTH major bleeding 3. all-cause death 4. CV (cardiac vascular death) 5. Myocardiac infarction 6. definite or probable stent thrombosis by Academic Research Consortium (ARC) definition 7. cerebrovascular accident (stroke) 8. cardiac death or Myocardiac infarction 9. cardiac death , Myocardiac infarction or stent thrombosis 10. cardiacvascular death, Myocardiac infarction or cerebrovascular accident (stroke) 11. TLR, target lesion revascularization 12. TVR, target vessel revascularization 13. any revascularization

—

Countries

Korea, Republic of

Contacts

Public ContactBobae Park

Dong-A University Hospital

pbb1231@naver.com+82-51-240-2555

Outcome results